Ignite Creation Date:
2024-05-06 @ 7:54 AM
Last Modification Date:
2024-10-26 @ 11:53 AM
Study NCT ID:
NCT02624271
Status:
COMPLETED
Last Update Posted:
2023-11-15
First Post:
2015-12-03
Brief Title:
Diagnosis of Gastric Precancerous Lesions by a Blood Test GastroPanel in Patients With Increased Gastric Cancer Risk
Sponsor:
Nantes University Hospital
Organization:
Nantes University Hospital
Study Overview
Official Title:
Non Invasive Diagnosis of Gastric Precancerous Lesions by GastroPanel Blood Test in Patients With Increased Gastric Cancer Risk a French Multicenter Study
Status:
COMPLETED
Status Verified Date:
2019-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GASTRO-PRA
Brief Summary:
Despite the declining incidence gastric cancer GC remains the second leading cause of cancer death worldwide In France it is the second digestive cancer with 7000 new cases per year It is now well demonstrated that patients with H pylori infection atrophic gastritis and intestinal metaplasia have a high risk of developing GC It is therefore important to detect these pre-neoplastic lesions at an early stage to improve patients prognosis
Thus the aim of this project is to investigate the possible screening of gastric precancerous lesions by a blood test GastroPanel in France in patients with oesophagogastroduodenoscopy EGD prescription
Thus the aim of this project is to investigate the possible screening of gastric precancerous lesions by a blood test GastroPanel in France in patients with oesophagogastroduodenoscopy EGD prescription
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None